1. Home
  2. MYGN vs KYN Comparison

MYGN vs KYN Comparison

Compare MYGN & KYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MYGN
  • KYN
  • Stock Information
  • Founded
  • MYGN 1991
  • KYN 2004
  • Country
  • MYGN United States
  • KYN United States
  • Employees
  • MYGN N/A
  • KYN N/A
  • Industry
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • KYN Finance/Investors Services
  • Sector
  • MYGN Health Care
  • KYN Finance
  • Exchange
  • MYGN Nasdaq
  • KYN Nasdaq
  • Market Cap
  • MYGN 2.0B
  • KYN 2.0B
  • IPO Year
  • MYGN 1995
  • KYN N/A
  • Fundamental
  • Price
  • MYGN $17.61
  • KYN $11.93
  • Analyst Decision
  • MYGN Buy
  • KYN
  • Analyst Count
  • MYGN 12
  • KYN 0
  • Target Price
  • MYGN $28.18
  • KYN N/A
  • AVG Volume (30 Days)
  • MYGN 785.8K
  • KYN 561.5K
  • Earning Date
  • MYGN 11-07-2024
  • KYN 01-01-0001
  • Dividend Yield
  • MYGN N/A
  • KYN 8.99%
  • EPS Growth
  • MYGN N/A
  • KYN N/A
  • EPS
  • MYGN N/A
  • KYN 0.71
  • Revenue
  • MYGN $802,200,000.00
  • KYN N/A
  • Revenue This Year
  • MYGN $13.95
  • KYN N/A
  • Revenue Next Year
  • MYGN $9.71
  • KYN N/A
  • P/E Ratio
  • MYGN N/A
  • KYN $13.79
  • Revenue Growth
  • MYGN 14.78
  • KYN N/A
  • 52 Week Low
  • MYGN $16.00
  • KYN $7.84
  • 52 Week High
  • MYGN $29.30
  • KYN $9.88
  • Technical
  • Relative Strength Index (RSI)
  • MYGN 21.43
  • KYN 64.17
  • Support Level
  • MYGN $16.86
  • KYN $11.48
  • Resistance Level
  • MYGN $22.92
  • KYN $11.84
  • Average True Range (ATR)
  • MYGN 0.97
  • KYN 0.18
  • MACD
  • MYGN -0.44
  • KYN -0.02
  • Stochastic Oscillator
  • MYGN 10.47
  • KYN 94.70

About MYGN Myriad Genetics Inc.

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

Share on Social Networks: